Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Employers should consider requiring documented diagnoses, evidence-based prior authorization, and stepped therapy, plus lifestyle programs before approving GLP-1s for weight loss to curb long-term spend
Tirzepatide, a dual GLP-1/GIP agonist, is already approved as Mounjaro (for type 2 diabetes) and Zepbound (for obesity)
$99/mo Member pricing on BioTE, priority labs, and quarterly NP check-ins
GLP-1 medications were originally developed for type 2 diabetes and have extensive evidence supporting their use for this condition
There should also be other clinical trials of wider ranges to ascertain the efficacy and safety of different formulations, including S-acetyl-glutathione
US$ 28.01
US$ 20.09
US$ 21.05
US$ 27.10
US$ 25.22
US$ 23.59
